Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation

Cancer Science

Volumn 96, Issue 1, 2005, Pages 48-53

  Tsuda, Hitoshi ^a,c   Morita, Daisaku ^a   Kimura, Mikihiko ^a   Shinto, Eiji ^a   Ohtsuka, Yukiko ^a   Matsubara, Osamu ^a   Inazawa, Johji ^b,c   Tamaki, Kuniyoshi ^a   Mochizuki, Hidetaka ^a   Tamai, Seiichi ^a   Hiraide, Hoshio ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN S 100; STEM CELL FACTOR; VIMENTIN; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MASTECTOMY; MESENCHYME CELL; MYOEPITHELIUM CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; BREAST TUMOR; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; UPREGULATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VIMENTIN;

EID: 20044381463     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00009.x     Document Type: Article

References (36)

1. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-KIT in human mast cell leukemia cell line causing ligand-independent activation of c-KIT product. J Clin Invest 1993; 92: 1736-44.
2. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37: S16-S22.
3. Isozaki K, Hirota S, Nakama A, Miyagawa J, Shinomura Y, Xu Z, Nomura S, Kitamura Y. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 1995; 109: 456-64.
4. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P. Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family-oncogene activation of v-KIT involves deletion of extracellular domain and C terminus. EMBO J 1998; 7 1003-11.
5. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341-51.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
7. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen C-J, Xiao S, Tuveson DA, Demetri GD, Fletcher CDM, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-21.
8. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y. Effect of c-KIT mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-300.
9. Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, Seto M, Seito T, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R. Expression of the c-KIT protein in human solid tumors and in corresponding fetal and adult normal tissue. Am J Pathol 1993; 142: 339-46.
10. Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S, Ogawa M. Immunohistochemical expression of the c-KIT proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996; 73: 1233-6.
11. Palmu S, Söderström KO, Quazi K, Isola J, Salminen E. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res 2002; 22: 411-4.
12. Tsuura Y, Suzuki T, Honma K, Sano M. Expression of c-KIT protein in proliferative lesions of human breast: Sexual difference and close association with phosphotyrosine status. J Cancer Res Clin Oncol 2002; 128: 239-46.
13. Hayes DF, Thor AD. c-erbB-2 in breast caricer: Development of a clinically useful marker. Semin Oncol 2002; 29: 231-45.
14. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 4: 791-808.
15. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002; 71: 67-75.
16. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999; 53: 167-76.
17. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998; 433 119-29.
18. Wetzels RH, Holland R, van Haelst UJ, Lane EB, Leigh IM, Ramaekers FC. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am J Pathol 1989; 134: 571-9.
19. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torborst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
20. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Laboratory Invest 2000; 80: 1943-9.
21. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159: 2249-56.
22. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example ot human fibroblastic tumors. Am J Pathol 2001; 158:1245-51.
23. Hendriks Y, Franken P, Dierssen JW, De Leeuw W, Wijnen J, Dreef E, Tops C, Breuning M, Brocker-Vriends A, Vasen H, Fodde R, Morreau H. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003; 162: 469-77.
24. World Health Organization. International Histological Classification of Tumors No. 2. Histological Typing of Breast Tumors. 2nd edn. World Health Organization, Geneva 1981; 17-25.
25. Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer, 15th edn. Kanehara Shuppan, Tokyo 2004. (In Japanese.)
26. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76: 378-82.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
28. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 1989; 20: 732-40.
29. Wargotz ES, Norris H.J. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989; 20: 628-35.
30. Rosen PP. Breast Pathology. Lippincott-Raven, Philadelphia 1997; 355-95.
31. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000; 37: 175-81.
32. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000; 24: 197-202.
33. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
34. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21 4342-9.
35. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
36. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imafinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.